The American Journal of Managed Care22 天
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...
Nature4 年
Accelerating the development of cancer immunotherapies
The Center of Molecular Immunology, a core institute of the Cuban organization of Biotechnology and Pharmaceutical Industries, BioCubaFarma, specializes in the development and manufacture of ...
Pharmaceutical Technology24 天
Interferon gamma-1b by Amgen for Myelodysplastic Syndrome: Likelihood of Approval
Interferon gamma-1b is under clinical development by Amgen and currently in Phase II for Myelodysplastic Syndrome.
Pharmaceutical Technology24 天
Sargramostim by Partner Therapeutics for Metastatic Melanoma: Likelihood of Approval
Sargramostim is under clinical development by Partner Therapeutics and currently in Phase III for Metastatic Melanoma.